ScienceGate
Advanced Search
Author Search
Journal Finder
Blog
Sign in / Sign up
ScienceGate
Search
Author Search
Journal Finder
Blog
Sign in / Sign up
OP0218 Efficacy and safety results of guselkumab, an anti-il23 monoclonal antibody, in patients with active psoriatic arthritis over 24 weeks: a phase 2a, randomized, double-blind, placebo-controlled study
Mapping Intimacies
◽
10.1136/annrheumdis-2017-eular.1164
◽
2017
◽
Cited By ~ 6
Author(s):
A Deodhar
◽
A Gottlieb
◽
W-H Boehncke
◽
B Dong
◽
Y Wang
◽
...
Keyword(s):
Monoclonal Antibody
◽
Psoriatic Arthritis
◽
Controlled Study
◽
Efficacy And Safety
◽
Double Blind
◽
Double Blind Placebo
Download Full-text
Related Documents
Cited By
References
228. Secukinumab, A Human Anti-Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis and Inhibits Radiographic Progression: Efficacy and Safety Data from a Phase 3 Randomized, Multicentre, Double-Blind, Placebo-Controlled Study
Rheumatology
◽
10.1093/rheumatology/kev089.115
◽
2015
◽
Keyword(s):
Monoclonal Antibody
◽
Psoriatic Arthritis
◽
Radiographic Progression
◽
Safety Data
◽
Controlled Study
◽
Efficacy And Safety
◽
Phase 3
◽
Double Blind
◽
Double Blind Placebo
◽
Interleukin 17A
Download Full-text
Long‐term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin‐23, Through 2 Years: Results from a Phase 3, Randomized, Double‐blind, Placebo‐controlled Study Conducted in Biologic‐naïve Patients with Active Psoriatic Arthritis
Arthritis & Rheumatology
◽
10.1002/art.42010
◽
2021
◽
Author(s):
Iain B. McInnes
◽
Proton Rahman
◽
Alice B. Gottlieb
◽
Elizabeth C. Hsia
◽
Alexa P. Kollmeier
◽
...
Keyword(s):
Monoclonal Antibody
◽
Psoriatic Arthritis
◽
Controlled Study
◽
Efficacy And Safety
◽
Phase 3
◽
Double Blind
◽
Double Blind Placebo
◽
Term Efficacy
◽
Interleukin 23
Download Full-text
Efficacy and safety of guselkumab, an anti-IL23 Monoclonal antibody, in patients with active psoriatic arthritis: A phase 2a, randomized, double-blind, placebo-controlled study
Journal of the American Academy of Dermatology
◽
10.1016/j.jaad.2017.04.443
◽
2017
◽
Vol 76
(6)
◽
pp. AB111
◽
Cited By ~ 1
Keyword(s):
Monoclonal Antibody
◽
Psoriatic Arthritis
◽
Controlled Study
◽
Efficacy And Safety
◽
Double Blind
◽
Double Blind Placebo
Download Full-text
Faculty Opinions recommendation of Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
◽
10.3410/f.725732407.793547378
◽
2018
◽
Author(s):
Maria Laura Bertolaccini
Keyword(s):
Systemic Lupus Erythematosus
◽
Monoclonal Antibody
◽
Lupus Erythematosus
◽
Phase Iii
◽
Controlled Study
◽
Efficacy And Safety
◽
Systemic Lupus
◽
Double Blind
◽
Double Blind Placebo
◽
B Cell Activating Factor
Download Full-text
OP0234 EFFICACY AND SAFETY OF BRODALUMAB, AN ANTI-INTERLEUKIN-17 RECEPTOR A MONOCLONAL ANTIBODY, IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: A 16 WEEK RESULTS OF A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
10.1136/annrheumdis-2019-eular.6888
◽
2019
◽
Cited By ~ 2
Author(s):
James Cheng-Chung Wei
◽
Tae-Hwan Kim
◽
Mitsumasa Kishimoto
◽
Takuya Morishige
◽
Naoki Ogusu
◽
...
Keyword(s):
Monoclonal Antibody
◽
Axial Spondyloarthritis
◽
Controlled Study
◽
Interleukin 17
◽
Efficacy And Safety
◽
Phase 3
◽
Double Blind
◽
Double Blind Placebo
Download Full-text
Faculty Opinions recommendation of Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
◽
10.3410/f.718257967.793494565
◽
2014
◽
Author(s):
Christian Jorgensen
◽
Yves-Marie Pers
Keyword(s):
Monoclonal Antibody
◽
Psoriatic Arthritis
◽
Tumour Necrosis Factor
◽
Tumour Necrosis
◽
Efficacy And Safety
◽
Phase 3
◽
Double Blind
◽
Double Blind Placebo
◽
Factor Therapy
◽
Necrosis Factor
Download Full-text
OP0174 Efficacy and Safety of Ustekinumab in Psoriatic Arthritis Patients with Spondylitis and Peripheral Joint Involvement: Results from a Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study
Annals of the Rheumatic Diseases
◽
10.1136/annrheumdis-2015-eular.3096
◽
2015
◽
Vol 74
(Suppl 2)
◽
pp. 136.1-136
◽
Cited By ~ 3
Author(s):
A. Kavanaugh
◽
L. Puig
◽
A.B. Gottlieb
◽
C. Ritchlin
◽
Y. You
◽
...
Keyword(s):
Psoriatic Arthritis
◽
Controlled Study
◽
Joint Involvement
◽
Efficacy And Safety
◽
Phase 3
◽
Double Blind
◽
Double Blind Placebo
Download Full-text
A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis
Arthritis & Rheumatism
◽
10.1002/art.34330
◽
2012
◽
Vol 64
(6)
◽
pp. 1730-1739
◽
Cited By ~ 100
Author(s):
Michael Yellin
◽
Igor Paliienko
◽
Andra Balanescu
◽
Semen Ter-Vartanian
◽
Vira Tseluyko
◽
...
Keyword(s):
Rheumatoid Arthritis
◽
Monoclonal Antibody
◽
Phase Ii
◽
Controlled Study
◽
Efficacy And Safety
◽
Double Blind
◽
Double Blind Placebo
Download Full-text
Results of A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of The Efficacy And Safety of Sirukumab, An Anti-IL-6 Cytokine Monoclonal Antibody, In Patients with Active Rheumatoid Arthritis Despite Disease-Modifying Anti-Rheumatic Drug Treatment (Sirround-D)
Value in Health
◽
10.1016/j.jval.2016.09.1074
◽
2016
◽
Vol 19
(7)
◽
pp. A531
◽
Cited By ~ 2
Author(s):
T Takeuchi
◽
C Thorne
◽
G Karpouzas
◽
S Sheng
◽
W Xu
◽
...
Keyword(s):
Rheumatoid Arthritis
◽
Monoclonal Antibody
◽
Active Rheumatoid Arthritis
◽
Controlled Study
◽
Efficacy And Safety
◽
Phase 3
◽
Double Blind
◽
Double Blind Placebo
◽
Disease Modifying
◽
Rheumatic Drug
Download Full-text
OP0308 Efficacy and safety results of guselkumab in patients with active psoriatic arthritis over 56 weeks from a phase 2a, randomised, double-blind, placebo-controlled study
10.1136/annrheumdis-2018-eular.2059
◽
2018
◽
Cited By ~ 2
Author(s):
A. Deodhar
◽
A.B. Gottlieb
◽
W.-H. Boehncke
◽
B. Dong
◽
Y. Wang
◽
...
Keyword(s):
Psoriatic Arthritis
◽
Controlled Study
◽
Efficacy And Safety
◽
Double Blind
◽
Double Blind Placebo
Download Full-text
Sign in / Sign up
Close
Export Citation Format
Close
Share Document
Close